Results from a study of epratuzumab were released today. It did not meet its primary endpoint of clinically reducing the severity of lupus in people with mild to moderate disease. The following is a statement from Sandra C. Raymond, President and CEO
Lupus Foundation of America Hosts Capitol Conversation on 21st Century Cures Moderated by Chuck Todd
National Advocacy Awards Dinner recognizes leaders from Congress, federal agencies, industry and the research community.
Lupus Foundation of America Hosts Awards Dinner & 21st Century Cures Discussion
People with lupus need and deserve a full arsenal of treatments. With many new and innovative drugs for lupus in the drug pipeline, these highly anticipated treatments will mean nothing if people with lupus cannot afford them.
A new research study by Foundation grantee Dr. Laurence Morel identifies a lupus related gene that affects adult mesenchymal stem cells. Read more.
Part of a new analysis from the ongoing Hopkins Lupus Cohort provides new knowledge that may help physicians make decisions about gradually reducing corticosteroid doses in people with lupus.
When the Lupus Foundation of America became aware of a hydroxychloroquine (Plaquenil®) shortage, we set out to discover the root of problem. While we still have limited information, we want to alert our constituents to the facts of the situation.
At a scientific symposium in San Francisco last month, some of the country’s foremost experts on lupus shared their insights about the current state of lupus clinical trial design. Read more.